<DOC>
	<DOCNO>NCT01023139</DOCNO>
	<brief_summary>There study look sustained weight loss adolescent population . This study use multidisciplinary approach along pharmacotherapy ( use Meridia ) motivate establish behavior change adolescent ( 12-18yo ) first phase study . The second phase lose least 5 % BMI randomize one two group . This first group intervention follow 3 6 month assess weight loss maintenance . The second group continue monthly behavior modification also evaluate 3 6 month . The hypothesis propose , 1 ) sustain weight loss end one year arm compare baseline BMI , 2 ) arm behavioral therapy intervention successful intervention weight loss maintenance .</brief_summary>
	<brief_title>`` Efficacy Adolescents Continued Behavior Modification Following Six Month Sibutramine-based Weight Management Intervention ''</brief_title>
	<detailed_description />
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Age : &gt; = 12 &lt; = 18 year old time screen BMI least U.S. weight mean 95th percentile base age sex Willing lose weight meet continue study medication 12 month treatment period even he/she meet personal weight loss goal . Willing start new weight loss product Males nonpregnant female ( pregnancy determine selfreport ) Females childbearing potential practicing acceptable method contraception Weight loss ≥ 10 pound previous 3 month Active gastrointestinal disorder ( except GERD ) peptic ulcer disease , irritable bowel disease , gallbladder condition ( last 3 month ) ; inflammable bowel disease ( Crohn 's ulcerative colitis , celiac sprue ) At least 2 3 blood pressure read either systolic diastolic ≥ 95 % ile height age pulse ≥95 beat per minute initial visit . Drug treat diabetes mellitus drug treat hypertension Drugs and/or supplement administer first time withdrawn past 6 month significant impact body weight digestion ( see Appendix D ) Inability unwillingness comply protocol requirement , i.e . consider unfit study participation , unable swallow pill . Unwilling avoid consumption alcoholic beverage Smoking start smoke cessation program within past six month Previous treatment prescription sibutramine ( Meridia® ) History recurrent nephrolithiasis Major psychiatric eat disorder ( i.e. , major depressive disorder , bipolar disorder , anorexia nervosa , bulimia laxative abuse ) Kidney , liver , thyroid disorder Drugs contraindicate concomitant use sibutramine ( Meridia® ) within last 4 week ( See Appendix E ) Cardiovascular disease ( include arrhythmia , heart failure congenital heart defect History bleeding problem , hemophilia History migraine headache ; seizure ; stroke ministroke History Pulmonary hypertension Osteopenia osteoporosis Selfreport current recreational drug use overused prescription medication History glaucoma Females selfreport pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Adolescent</keyword>
	<keyword>Obesity</keyword>
	<keyword>Pharmacotherapy</keyword>
	<keyword>Sibutramine</keyword>
</DOC>